Ruben Tejada, MD
Internal Medicine · Rogers, ARNPI 1053473231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,346, 7.5 times the $179 reported in 2019. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$834
- AbbVie$751
- Amgen$570
- Antares Pharma, Inc.$549
- Kowa Pharmaceuticals America, Inc.$384
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,025100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $1,075 |
| AstraZeneca | 16 | $834 |
| AbbVie(2 entities) | 43 | $751 |
| Amgen(2 entities) | 48 | $570 |
| Antares Pharma, Inc. | 39 | $549 |
| Kowa Pharmaceuticals America, Inc. | 32 | $384 |
| Pfizer | 2 | $221 |
| Dexcom, Inc. | 4 | $198 |
| GSK | 13 | $183 |
| Esperion Therapeutics, Inc. | 7 | $159 |
| Idorsia Pharmaceuticals US Inc | 8 | $154 |
| Lilly USA, LLC | 9 | $139 |
| Gilead | 1 | $100 |
| Mylan Specialty L.p. | 5 | $92 |
| Boehringer Ingelheim | 4 | $76 |
| Merck | 4 | $68 |
| Eisai Inc. | 4 | $57 |
| Abbott | 3 | $47 |
| Halozyme Inc | 2 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $37 |
| Bayer | 2 | $34 |
| Corium, LLC | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| IBSA Pharma Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Kaleo, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$367
- AIRSUPRA$297
- FARXIGA$297
- RYBELSUS$234
- BREZTRI$172
- DEXCOM G7 GSS (161)$145
- DEXCOM STELO GLUCOSE BIOSENSOR$145
- Wegovy$121
- NURTEC ODT$112
- QUVIVIQ$110
- ZAVZPRET$109
- Epclusa$100
How this compares
$6,037 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $59,222 |
| RybelsusSemaglutide | 35 | $37,074 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $34,685 |
| MounjaroTirzepatide | 11 | $19,947 |
| Xigduo XrDapaglifloz Propaned/Metformin | 25 | $18,918 |
| FarxigaDapagliflozin Propanediol | 28 | $15,485 |
| LinzessLinaclotide | 16 | $11,104 |
| BrilintaTicagrelor | 11 | $4,996 |
| Celecoxib | 92 | $4,688 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,026 |
| Levemir FlexpenInsulin Detemir | 12 | $3,517 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $1,756 |
| Testosterone Cypionate | 44 | $1,665 |
| Levetiracetam | 16 | $1,582 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 56 | $1,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,075 | $96,29694 claims |
| MerckJanumet | $68 | $34,68541 claims |
| AstraZenecaFarxiga, Brilinta | $834 | $20,48139 claims |
| Lilly USA, LLCMounjaro | $139 | $19,94711 claims |
| AbbVieLinzess, Armour Thyroid | $751 | $11,46928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Rogers
- Stuart BensonRogers$24K
- Douglas EddyRogers$9K
- Kristy JonesRogers$6K
- David PyleJonesboro$93K
- Aaron StrobelLittle Rock$32K
- Purnima SarkarEarle$21K
- John NorwoodJonesboro$21K
- Ahmed AliConway$18K
- Jeremy DavisLittle Rock$17K
- Tyree SealsFort Smith$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.